IFN-α subtypes: Distinct biological activities in anti-viral therapy

British Journal of Pharmacology

Volumn 168, Issue 5, 2013, Pages 1048-1058

  Gibbert, K ^a   Schlaak, J F ^a   Yang, D ^b   Dittmer, U ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Tongji Hospital   (China)

Author keywords

IFN subtypes; immunomodulation; immunotherapy; viral infection

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA1 INTERFERON; ALPHA10 INTERFERON; ALPHA11 INTERFERON; ALPHA12 INTERFERON; ALPHA14 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA4 INTERFERON; ALPHA5 INTERFERON; ALPHA6 INTERFERON; ALPHA9 INTERFERON; BETA INTERFERON; CONSENSUS INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GAG PROTEIN; INTERFERON; JANUS KINASE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BINDING AFFINITY; CHRONICITY; CYTOMEGALOVIRUS INFECTION; DNA IMMUNIZATION; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVATION; GENE; GENE ACTIVATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLUENZA; INNATE IMMUNITY; INTERFERON STIMULATED GENE; LUNG DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RETROVIRUS INFECTION; REVIEW; ROTAVIRUS INFECTION; SEROCONVERSION; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS VIRUS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; INTERFERON TYPE I; PROTEIN SUBUNITS; VIRUS DISEASES;

EID: 84874244715     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12010     Document Type: Review

References (111)

1. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. (2011). Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141: 1231-1239. e1231-e1232.
2. Akira S, Takeda K, (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499-511.
3. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL, (2004). Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 190: 1841-1849.
4. Austin BA, James C, Silverman RH, Carr DJ, (2005). Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol 175: 1100-1106.
5. Austin BA, James CM, Harle P, Carr DJ, (2006). Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol Proced Online 8: 55-62.
6. Baig E, Fish EN, (2008). Distinct signature type I interferon responses are determined by the infecting virus and the target cell. Antivir Ther 13: 409-422.
7. Barchet W, Wimmenauer V, Schlee M, Hartmann G, (2008). Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 20: 389-395.
8. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, et al. (2011). Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 8: 75.
9. Biron CA, Sonnenfeld G, Welsh RM, (1984). Interferon induces natural killer cell blastogenesis in vivo. J Leukoc Biol 35: 31-37.
10. Blatt LM, Davis JM, Klein SB, Taylor MW, (1996). The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16: 489-499.
11. Castelruiz Y, Larrea E, Boya P, Civeira MP, Prieto J, (1999). Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology 29: 1900-1904.
12. Clemens MJ, Elia A, (1997). The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17: 503-524.
13. Cull VS, Bartlett EJ, James CM, (2002). Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106: 428-437.
14. Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM, (2003). Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101: 2727-2735.
15. Der SD, Zhou A, Williams BR, Silverman RH, (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623-15628.
16. Easlick J, Szubin R, Lantz S, Baumgarth N, Abel K, (2010). The early interferon alpha subtype response in infant macaques infected orally with SIV. J Acquir Immune Defic Syndr 55: 14-28.
17. Epperson DE, Arnold D, Spies T, Cresswell P, Pober JS, Johnson DR, (1992). Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J Immunol 149: 3297-3301.
18. Erlandsson L, Blumenthal R, Eloranta ML, Engel H, Alm G, Weiss S, et al. (1998). Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Curr Biol 8: 223-226.
19. Feld JJ, Hoofnagle JH, (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
20. Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, et al. (2004). IFN-alpha subtypes differentially affect human T cell motility. J Immunol 173: 1663-1670.
21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
22. Fung MC, Sia SF, Leung KN, Mak NK, (2004). Detection of differential expression of mouse interferon-alpha subtypes by polymerase chain reaction using specific primers. J Immunol Methods 284: 177-186.
23. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, et al. (2006). Impact of protein kinase PKR in cell biology: from anti-viral to antiproliferative action. Microbiol Mol Biol Rev 70: 1032-1060.
24. Gerlach N, Gibbert K, Alter C, Nair S, Zelinskyy G, James CM, et al. (2009). Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol 39: 136-146.
25. Gibbert K, Joedicke JJ, Meryk A, Trilling M, Francois S, Duppach J, et al. (2012). Interferon alpha subtype 11 activates NK cells and enables control of retroviral infection. Plos Pathog 8: e1002868. doi: 10.1371/journal.ppat. 1002868
26. Gibbert K, Dietze KK, Zelinskyy G, Lang KS, Barchet W, Kirschning CJ, et al. (2010). Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 185: 6179-6189.
27. Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA, (2006). Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of toll-like receptor ligands correlates with beta interferon production. Journal of Virology 80: 9943-9950.
28. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC, (1976). Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295: 517-522.
29. Grumbach IM, Fish EN, Uddin S, Majchrzak B, Colamonici OR, Figulla HR, et al. (1999). Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to the anti-viral effects of IFN-beta compared with IFN-alpha. J Interferon Cytokine Res 19: 797-801.
30. Haller O, Staeheli P, Kochs G, (2007). Interferon-induced Mx proteins in anti-viral host defense. Biochimie 89: 812-818.
31. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ, (2004). Characterization of the type I interferon locus and identification of novel genes. Genomics 84: 331-345.
32. Harle P, Cull V, Agbaga MP, Silverman R, Williams BR, James C, et al. (2002). Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. J Virol 76: 6558-6567.
33. Hermann P, Rubio M, Nakajima T, Delespesse G, Sarfati M, (1998). IFN-alpha priming of human monocytes differentially regulates gram-positive and gram-negative bacteria-induced IL-10 release and selectively enhances IL-12p70, CD80, and MHC class I expression. J Immunol 161: 2011-2018.
34. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S, (2003). Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358.
35. Hilkens CM, Schlaak JF, Kerr IM, (2003). Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 171: 5255-5263.
36. Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, et al. (2012). Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 90: 774-783.
37. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
38. Honda K, Takaoka A, Taniguchi T, (2006). Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25: 349-360.
39. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. (1988). Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95: 1318-1325.
40. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. (2005). Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42: 724-731.
41. Hunter CA, Gabriel KE, Radzanowski T, Neyer LE, Remington JS, (1997). Type I interferons enhance production of IFN-gamma by NK cells. Immunol Lett 59: 1-5.
42. Isaacs A, Lindenmann J, (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267.
43. Isogawa M, Robek MD, Furuichi Y, Chisari FV, (2005). Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. Journal of Virology 79: 7269-7272.
44. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. (2001). Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1452-1457.
45. Jaks E, Gavutis M, Uze G, Martal J, Piehler J, (2007). Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525-539.
46. James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, et al. (2007). Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25: 1856-1867.
47. Keating SE, Baran M, Bowie AG, (2011). Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol 32: 574-581.
48. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K, (2005). Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650.
49. Koyama T, Sakamoto N, Tanabe Y, Nakagawa M, Itsui Y, Takeda Y, et al. (2006). Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 34: 41-49.
50. Kraft AR, Krux F, Schimmer S, Ohlen C, Greenberg PD, Dittmer U, (2007). CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 109: 2982-2984.
51. Larrea E, Aldabe R, Riezu-Boj JI, Guitart A, Civeira MP, Prieto J, et al. (2004). IFN-alpha5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2',5'-oligoadenylate synthetase than IFN-alpha2 in liver cells. J Interferon Cytokine Res 24: 497-503.
52. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, et al. (2011). Binding and activity of all human alpha interferon subtypes. Cytokine 56: 282-289.
53. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF, (2001). Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
54. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. (2003). Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015.
55. Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, et al. (2006a). Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176: 4682-4689.
56. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, et al. (2006b). Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176: 2074-2078.
57. Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A, et al. (2003). Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res 23: 745-756.
58. Li BL, Zhao XX, Liu XY, Kim HS, Raska K Jr, Ortaldo JR, et al. (1990). Alpha-interferon structure and natural killer cell stimulatory activity. Cancer Res 50: 5328-5332.
59. Li L, Sherry B, (2010). IFN-alpha expression and anti-viral effects are subtype and cell type specific in the cardiac response to viral infection. Virology 396: 59-68.
60. Liu C, Zhu H, Subramanian GM, Moore PA, Xu Y, Nelson DR, (2007). Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol Res 37: 941-947.
61. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, et al. (2003). Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171: 4320-4328.
62. Loseke S, Grage-Griebenow E, Wagner A, Gehlhar K, Bufe A, (2003). Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays. J Immunol Methods 276: 207-222.
63. Lu Y, Xu Y, Yang D, Kemper T, Roggendorf M, Lu M, (2008). Molecular characterization of woodchuck type I interferons and their expression by woodchuck peripheral blood lymphocytes. Cytokine 41: 127-135.
64. McClary H, Koch R, Chisari FV, Guidotti LG, (2000). Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the anti-viral effects of cytokines. Journal of Virology 74: 2255-2264.
65. McHutchison JG, Poynard T, (1999). Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 19 (Suppl. 1): 57-65.
66. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. (2007). Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46: 1341-1349.
67. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
68. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. (2009). Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136: 2169-2179. e2161-e2164.
69. Marie I, Durbin JE, Levy DE, (1998). Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17: 6660-6669.
70. Mo XY, Ma W, Zhang Y, Zhao H, Deng Y, Yuan W, et al. (2007). Microarray analyses of differentially expressed human genes and biological processes in ECV304 cells infected with rubella virus. J Virol 79: 1783-1791.
71. Moll HP, Maier T, Zommer A, Lavoie T, Brostjan C, (2011). The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. Cytokine 53: 52-59.
72. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S, (2009). Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 29: 4778-4787.
73. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, et al. (1980). Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284: 316-320.
74. Neil SJ, Zang T, Bieniasz PD, (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
75. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, et al. (2010). Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 139: 1267-1276.
76. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. (1998). Hepatitis C viral dynamics in vivo and the anti-viral efficacy of interferon-alpha therapy. Science 282: 103-107.
77. NIH (1997). National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26 (3 Suppl. 1): 2S-10S.
78. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, et al. (2002). Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303: 540-548.
79. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW, (1992). A comparison of interferon-Con1 with natural recombinant interferons-alpha: anti-viral, antiproliferative, and natural killer-inducing activities. J Interferon Res 12: 55-59.
80. van Pesch V, Michiels T, (2003). Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype. J Biol Chem 278: 46321-46328.
81. van Pesch V, Lanaya H, Renauld JC, Michiels T, (2004). Characterization of the murine alpha interferon gene family. J Virol 78: 8219-8228.
82. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, et al. (2007). Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47: 174-182.
83. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
84. Puig M, Tosh KW, Schramm LM, Grajkowska LT, Kirschman KD, Tami C, et al. (2012). TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. J Leukoc Biol 91: 147-158.
85. Randall RE, Goodbourn S, (2008). Interferons and viruses: an interplay between induction, signalling, anti-viral responses and virus countermeasures. J Gen Virol 89 (Pt 1): 1-47.
86. Salazar-Mather TP, Ishikawa R, Biron CA, (1996). NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J Immunol 157: 3054-3064.
87. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. (2005). Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42: 329-333.
88. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N, (1998). Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441: 106-110.
89. Scagnolari C, Trombetti S, Selvaggi C, Carbone T, Monteleone K, Spano L, et al. (2011). In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol 24: 159-164.
90. Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uze G, et al. (2006). Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol 79: 1286-1294.
91. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
92. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. (2011). Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
93. Silverman RH, (2007). Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon anti-viral response. Journal of Virology 81: 12720-12729.
94. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD, (1998). How cells respond to interferons. Annu Rev Biochem 67: 227-264.
95. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, et al. (2010). Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138: 1885-1897.
96. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J, (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
97. Szubin R, Chang WL, Greasby T, Beckett L, Baumgarth N, (2008). Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J Interferon Cytokine Res 28: 749-763.
98. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. (2005). Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249.
99. Trapp S, Derby NR, Singer R, Shaw A, Williams VG, Turville SG, et al. (2009). Double-stranded RNA analog poly(I: C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 83: 884-895.
100. Trinchieri G, Santoli D, Granato D, Perussia B, (1981). Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells. Fed Proc 40: 2705-2710.
101. Tsang SL, Leung PC, Leung KK, Yau WL, Hardy MP, Mak NK, et al. (2007). Characterization of murine interferon-alpha 12 (MuIFN-alpha12): biological activities and gene expression. Cytokine 37: 138-149.
102. Uze G, Schreiber G, Piehler J, Pellegrini S, (2007). The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
103. Vazquez N, Schmeisser H, Dolan MA, Bekisz J, Zoon KC, Wahl SM, (2011). Structural variants of IFNalpha preferentially promote anti-viral functions. Blood 118: 2567-2577.
104. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. (2004). Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 40: 98-107.
105. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43: 250-256.
106. Witthoft T, (2008). Review of consensus interferon in the treatment of chronic hepatitis C. Biologics 2: 635-643.
107. Yamaoka T, Kojima S, Ichi S, Kashiwazaki Y, Koide T, Sokawa Y, (1999). Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells. J Interferon Cytokine Res 19: 1343-1349.
108. Yeow WS, Lai CM, Beilharz MW, (1997). The in vivo expression patterns of individual type I interferon genes in murine cytomegalovirus infections. Antiviral Res 34: 17-26.
109. Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, et al. (2008). Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 48: 407-417.
110. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, et al. (2010). Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 139: 1257-1266.
111. Zwarthoff EC, Mooren AT, Trapman J, (1985). Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res 13: 791-804.